Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06087978 | Study of RPT193 in Healthy Adult Male Subjects | PHASE1 | COMPLETED | 7 | — | — | Jul 5, 2023 | Oct 12, 2023 | Nov 29, 2023 | 1 | United States |
Amount (in mass equivalents of parent drug) of radioactive drug excreted as TRA in urine and feces
Percent (%) of radioactive drug excreted as TRA in urine and feces
Percent (%) of each drug-related material (parent and each metabolite) in whole blood, plasma, urine and feces
Calculation of area under the curve (AUC) in plasma and urine
| Arm | Type | Description |
|---|---|---|
| 14C RPT193 400 mg | EXPERIMENTAL | Radiolabelled RPT193 |
| Name | Type | Description |
|---|---|---|
| 14C RPT193 | DRUG | Radiolabelled RPT193 |
Inclusion Criteria: * Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to dosing * Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening Exclusion Criteria: * Is mentally or legally incapacitated or has significant emotional pro...